Pipes Feed Preview: ClinicalTrials.gov: COVID-19 | Last update posted in the last 14 days

  1. Light-based Immunomodulation for Guarding Against Human Respiratory Tract Infections

    Thu, 28 May 2026 04:00:00 -0000

    <b>Conditions</b>: COVID-19 Respiratory Infection; Influenza <br/><b>Interventions</b>: Device: RD-X19; Device: RD-X19 Sham <br/><b>Sponsors</b>: David Moss <br/><b>Not yet recruiting</b>

  2. A Prospective Study to Determine the Immunomodulatory Effect of Probiotics on the Immunogenicity of Anti-SARS-CoV-2 Vaccine Recipients Study.

    Thu, 28 May 2026 04:00:00 -0000

    <b>Conditions</b>: COVID-19; Immune Response <br/><b>Interventions</b>: Dietary Supplement: Probiotics; Other: Placebo <br/><b>Sponsors</b>: Grape King Bio Ltd.; Taipei Medical University Hospital <br/><b>Completed</b>

  3. An Experimental Medicine Multicenter Trial to Evaluate the Safety and Immunogenicity of Experimental Versus Authorized SARS-CoV-2 Vaccine Candidates as a Booster Dose in Healthy Participants Previously Vaccinated With Authorized mRNA SARS-CoV-2 Vaccines.

    Tue, 26 May 2026 04:00:00 -0000

    <b>Conditions</b>: Healthy Adults <br/><b>Interventions</b>: Biological: CD40.RBDv vaccine adjuvanted with Hiltonol®; Biological: CD40.Pan.CoV vaccine adjuvanted with Hiltonol®; Biological: Comirnaty® vaccine; Biological: Nuvaxovid™ vaccine <br/><b>Sponsors</b>: ANRS, Emerging Infectious Diseases <br/><b>Not yet recruiting</b>

  4. Respiratory Pathogen Distribution During and After the COVID-19 Pandemic

    Fri, 22 May 2026 04:00:00 -0000

    <b>Conditions</b>: Viral Respiratory Infection (e.g., Influenza); Bacterial Respiratory Infections <br/><b>Sponsors</b>: Hisar Intercontinental Hospital <br/><b>Completed</b>

  5. Fareon Open Label Device Clinical Trial

    Wed, 20 May 2026 04:00:00 -0000

    <b>Conditions</b>: Cognitive Dysfunction; Acquired Brain Injury; Traumatic Brain Injury <br/><b>Interventions</b>: Device: Fareon device <br/><b>Sponsors</b>: Icahn School of Medicine at Mount Sinai <br/><b>Not yet recruiting</b>

  6. Virological Surveillance of Acute Respiratory Infection in Primary Health Care in Metropolitan France

    Wed, 20 May 2026 04:00:00 -0000

    <b>Conditions</b>: Respiratory Tract Infections (RTI); Influenza -Like Illness; Influenza; COVID - 19; RSV Infections; Rhinovirus Infection; Metapneumovirus Infection <br/><b>Interventions</b>: Diagnostic Test: saliva sampling; Diagnostic Test: Nasopharyngeal swab <br/><b>Sponsors</b>: Institut National de la Santé Et de la Recherche Médicale, France <br/><b>Not yet recruiting</b>

  7. SARS-CoV-2 and Herpesvirus Inhibition for Ending Long COVID Dysfunction

    Tue, 19 May 2026 04:00:00 -0000

    <b>Conditions</b>: Post-acute Sequelae of COVID-19; Long COVID <br/><b>Interventions</b>: Drug: Valacyclovir; Drug: Celecoxib; Drug: Paxlovid; Drug: Placebo <br/><b>Sponsors</b>: Icahn School of Medicine at Mount Sinai <br/><b>Not yet recruiting</b>

  8. Diagnostic Accuracy of 2 cm Versus 4 cm Insertion Depth for Nasal Swabs for SARS-CoV-2 (COVID-19) Rapid Antigen Testing-A Randomized Controlled Trial

    Tue, 19 May 2026 04:00:00 -0000

    <b>Conditions</b>: COVID -19 <br/><b>Interventions</b>: Diagnostic Test: 4 cm nasal swab - left nostril; Diagnostic Test: 2 cm nasal swab in the left nostril; Diagnostic Test: 4 cm nasal swab - right nostril; Diagnostic Test: 2 cm nasal swab - right nostril <br/><b>Sponsors</b>: Rigshospitalet, Denmark <br/><b>Completed</b>

  9. SMAtteo COvid19 REgistry (SMACORE)

    Tue, 19 May 2026 04:00:00 -0000

    <b>Conditions</b>: COVID-19 <br/><b>Sponsors</b>: Fondazione IRCCS Policlinico San Matteo di Pavia <br/><b>Recruiting</b>

  10. Diagnostic and Clinical Management of Non-Obstructive Myocardial Ischemia in Patients With Long Covid-19 Syndrome and New Onset Chest Pain

    Thu, 28 May 2026 04:00:00 -0000

    <b>Conditions</b>: Angina (Stable); INOCA (Ischemia With Non Obstructive Coronary Artery Disease); Long COVID-19 Syndrome <br/><b>Interventions</b>: Diagnostic Test: Coronary functional test <br/><b>Sponsors</b>: Fundacion Investigacion Interhospitalaria Cardiovascular; Instituto de Salud Carlos III <br/><b>Active, not recruiting</b>

  11. A Study Evaluating MDX2301 in Healthy Adults and Adults at Higher Risk for Severe COVID-19.

    Mon, 18 May 2026 04:00:00 -0000

    <b>Conditions</b>: COVID -19; COVID-19 (Prevention) <br/><b>Interventions</b>: Biological: MDX2301; Biological: Normal Saline; Biological: Normal Saline; Biological: MDX2301 <br/><b>Sponsors</b>: ModeX Therapeutics, An OPKO Health Company <br/><b>Recruiting</b>

  12. Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)

    Fri, 29 May 2026 04:00:00 -0000

    <b>Conditions</b>: Post-Acute COVID-19 Syndrome <br/><b>Interventions</b>: Drug: Keytruda <br/><b>Sponsors</b>: National Institute of Neurological Disorders and Stroke (NINDS) <br/><b>Not yet recruiting</b>

  13. Analysis of Suicidal Behavior Among Children and Adolescents in the Auvergne-Rhone-Alpes Region During the Covid 19 Pandemic Period

    Mon, 18 May 2026 04:00:00 -0000

    <b>Conditions</b>: Suicidality; COVID -19 <br/><b>Interventions</b>: Other: Aggregated data collection; Other: Data collection and qualitative interview <br/><b>Sponsors</b>: Hospices Civils de Lyon <br/><b>Recruiting</b>

  14. Kisspeptin to Quantify GnRH Neuronal Function in Health and Disease

    Tue, 19 May 2026 04:00:00 -0000

    <b>Conditions</b>: Reproductive Disorder; Neurodegeneration; SARS-CoV 2; Long COVID <br/><b>Interventions</b>: Drug: Kisspeptin 112-121 <br/><b>Sponsors</b>: Stephanie B. Seminara, MD; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) <br/><b>Recruiting</b>

  15. A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes

    Fri, 29 May 2026 04:00:00 -0000

    <b>Conditions</b>: COVID-19 <br/><b>Interventions</b>: Drug: Aluminum Hydroxide Suspension; Biological: Boost-2867; Biological: CpG 7909; Other: Sodium Chloride, 0.9% <br/><b>Sponsors</b>: National Institute of Allergy and Infectious Diseases (NIAID) <br/><b>Active, not recruiting</b>

  16. Longitudinal Deep Phenotyping of Central Mechanisms in Dysosmia: A Pilot Study Using Electrobulbogram (EBG), Functional MRI (fMRI), and Diffusion-Weighted Imaging (DWI)

    Fri, 29 May 2026 04:00:00 -0000

    <b>Conditions</b>: Respiratory Tract Infection; Smell Disorder; Influenza; Rhinosinusitis; COVID-19; Depression; Parosmia; Hyposomia; Normosomia; Anosmia <br/><b>Sponsors</b>: National Institute on Deafness and Other Communication Disorders (NIDCD) <br/><b>Not yet recruiting</b>

  17. A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Variant-containing Formulations

    Tue, 19 May 2026 04:00:00 -0000

    <b>Conditions</b>: COVID-19 <br/><b>Interventions</b>: Biological: mRNA-1283.251 Variant-containing Formulation <br/><b>Sponsors</b>: ModernaTX, Inc. <br/><b>Recruiting</b>

  18. Multiparametric [18F]F-AraG Imaging in Post-Acute Sequelae of COVID-19 (PASC)

    Fri, 22 May 2026 04:00:00 -0000

    <b>Conditions</b>: PASC Post Acute Sequelae of COVID-19 <br/><b>Interventions</b>: Drug: A.1 - [¹⁸F]F-AraG PET/CT (90-min dynamic + 4-h static); Drug: A.2 - [¹⁸F]F-AraG PET/CT (60-min dynamic only); Drug: B.1 - [¹⁸F]F-AraG PET/CT (90-min dynamic + 4-h static); Drug: B.2 - [¹⁸F]F-AraG PET/CT (60-min dynamic only) <br/><b>Sponsors</b>: University of California, Davis; National Institute of Allergy and Infectious Diseases (NIAID); University of California, San Francisco <br/><b>Recruiting</b>

  19. A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised

    Thu, 28 May 2026 04:00:00 -0000

    <b>Conditions</b>: COVID-19 Infection <br/><b>Interventions</b>: Drug: ibuzatrelvir; Drug: remdesivir; Drug: placebo for ibuzatrelvir; Drug: placebo for remdesivir <br/><b>Sponsors</b>: Pfizer <br/><b>Recruiting</b>

  20. Low Dose Sirolimus in People With Post-Acute Sequelae of COVID-19 (PASC) Long COVID-19

    Mon, 18 May 2026 04:00:00 -0000

    <b>Conditions</b>: Long COVID-19 <br/><b>Interventions</b>: Drug: Low-dose sirolimus; Drug: Placebo <br/><b>Sponsors</b>: Icahn School of Medicine at Mount Sinai; PolyBio Research Foundation; The Anlyan Center <br/><b>Recruiting</b>

  21. Phase 1 Study on Bioavailability, Food Effect, and Drug-Drug Interaction of ALG-097558 Tablets in Healthy Volunteers

    Mon, 18 May 2026 04:00:00 -0000

    <b>Conditions</b>: COVID-19 <br/><b>Interventions</b>: Drug: ALG-097558; Drug: Dabigatran; Drug: Itraconazole; Other: Placebo <br/><b>Sponsors</b>: National Institute of Allergy and Infectious Diseases (NIAID) <br/><b>Completed</b>

  22. NE3107 in Adults With Neurological Symptoms of Long COVID

    Fri, 29 May 2026 04:00:00 -0000

    <b>Conditions</b>: Long COVID <br/><b>Interventions</b>: Drug: NE3107; Drug: Placebo <br/><b>Sponsors</b>: BioVie Inc. <br/><b>Active, not recruiting</b>

  23. RegiStry Of the multiFaceted medIcal cenTer

    Wed, 20 May 2026 04:00:00 -0000

    <b>Conditions</b>: Chronic Non-communicable Diseases; Cardiovascular Diseases; COVID-19; Multimorbidity <br/><b>Sponsors</b>: National Medical Research Center for Therapy and Preventive Medicine; State Healthcare Institution of the Tula Region Tula Regional Clinical Hospital <br/><b>Active, not recruiting</b>

  24. Retail COVID-19 Study

    Fri, 22 May 2026 04:00:00 -0000

    <b>Conditions</b>: COVID - 19 <br/><b>Interventions</b>: Biological: FDA approved mRNA vaccines <br/><b>Sponsors</b>: Biomedical Advanced Research and Development Authority <br/><b>Completed</b>

  25. Taurine Supplementation in Long COVID

    Wed, 27 May 2026 04:00:00 -0000

    <b>Conditions</b>: Long COVID <br/><b>Interventions</b>: Drug: Taurine; Drug: Placebo <br/><b>Sponsors</b>: University of Alberta; Canadian Institutes of Health Research (CIHR); University Health Network, Toronto <br/><b>Recruiting</b>

  26. A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ALG-097558 in Subjects With Renal Impairment and in Healthy Subjects With Normal Renal Function

    Tue, 26 May 2026 04:00:00 -0000

    <b>Conditions</b>: COVID 19 <br/><b>Interventions</b>: Drug: ALG-097558 <br/><b>Sponsors</b>: Aligos Therapeutics; National Institute of Allergy and Infectious Diseases (NIAID) <br/><b>Completed</b>

  27. A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease

    Thu, 28 May 2026 04:00:00 -0000

    <b>Conditions</b>: COVID-19 SARS-CoV-2 Infection <br/><b>Interventions</b>: Drug: ibuzatrelvir; Drug: placebo <br/><b>Sponsors</b>: Pfizer <br/><b>Recruiting</b>

  28. A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)

    Fri, 29 May 2026 04:00:00 -0000

    <b>Conditions</b>: Coronavirus Disease (COVID-19) <br/><b>Interventions</b>: Drug: Molnupiravir; Drug: Placebo <br/><b>Sponsors</b>: Merck Sharp & Dohme LLC <br/><b>Recruiting</b>

  29. Cross-Sectional Evaluation of Persistence of SARS-CoV-2 Remnants After Recovery From Acute Infection

    Fri, 22 May 2026 04:00:00 -0000

    <b>Conditions</b>: PASC Post Acute Sequelae of COVID-19 <br/><b>Sponsors</b>: National Institute of Neurological Disorders and Stroke (NINDS) <br/><b>Recruiting</b>

  30. Evaluation of Prevalence and Risk Factors of Persistent COVID-19 in Immunocompromised Patients

    Thu, 28 May 2026 04:00:00 -0000

    <b>Conditions</b>: Persistent COVID-19; B Cell Malignancies <br/><b>Interventions</b>: Other: Persisting SARS-CoV-2 infection <br/><b>Sponsors</b>: Maddalena Giannella <br/><b>Completed</b>

  31. A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ALG-097558 in Subjects With Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function

    Tue, 26 May 2026 04:00:00 -0000

    <b>Conditions</b>: COVID-19 <br/><b>Interventions</b>: Drug: ALG-097558 <br/><b>Sponsors</b>: Aligos Therapeutics; National Institute of Allergy and Infectious Diseases (NIAID) <br/><b>Completed</b>

  32. Low Dose Rapamycin in ME/CFS, Long-COVID, and Other Infection Associated Chronic Conditions

    Mon, 18 May 2026 04:00:00 -0000

    <b>Conditions</b>: Myalgic Encephalomyelitis; Long-COVID <br/><b>Interventions</b>: Drug: Rapamycin <br/><b>Sponsors</b>: Simmaron Research Inc.; Center For Complex Diseases-Seattle, WA; Sierra Internal Medicine, Incline Village, NV; Center for Complex Diseases- Palo Alto, CA; Simmaron Research Inc. R&D Lab, University of Wisconsin, Milwaukee (UWM); Bateman Horne Center, Salt Lake City, UT; Mayo Clinic <br/><b>Enrolling by invitation</b>

  33. Chronic-disease Self-management Program in Patients Living With Long-COVID in Puerto Rico

    Fri, 22 May 2026 04:00:00 -0000

    <b>Conditions</b>: Long Covid19 <br/><b>Interventions</b>: Other: "Tomando control de su salud" (Spanish Chronic Disease Self-Management) <br/><b>Sponsors</b>: University of Puerto Rico; National Institutes of Health (NIH) <br/><b>Completed</b>

  34. Evaluation of Concordance Between Exhaled Air Test (eBAM-CoV) and RT-PCR to Detect SARS-CoV-2

    Wed, 27 May 2026 04:00:00 -0000

    <b>Conditions</b>: SARS-CoV-2 Infection; COVID-19; Coronavirus <br/><b>Interventions</b>: Device: eBAM Cov Testing <br/><b>Sponsors</b>: Centre Hospitalier Universitaire de Nīmes; University of Nimes; brains' laboratory sas, FRANCE <br/><b>Recruiting</b>

  35. COVID-19 Transmission and Morbidity in Malawi

    Thu, 28 May 2026 04:00:00 -0000

    <b>Conditions</b>: SARS CoV 2 Infection; SARS CoV 2 Vaccination <br/><b>Sponsors</b>: Boston University; National Institute of Allergy and Infectious Diseases (NIAID); Kamuzu University of Health Sciences; Burnet Institute <br/><b>Recruiting</b>

  36. COVID19 OutcomeS in Myeloma and the Impact of VaCcines

    Mon, 18 May 2026 04:00:00 -0000

    <b>Conditions</b>: Multiple Myeloma <br/><b>Interventions</b>: Other: Patient Reported Outcomes <br/><b>Sponsors</b>: ASH Research Collaborative; ModernaTX, Inc. <br/><b>Completed</b>

  37. Vaccine Hesitancy in Black/African Americans With Rheumatic Diseases

    Fri, 29 May 2026 04:00:00 -0000

    <b>Conditions</b>: Rheumatic Diseases; COVID-19 Vaccine; COVID-19; SLE <br/><b>Interventions</b>: Behavioral: COVID-19 vaccine and booster training, and importance <br/><b>Sponsors</b>: Northwestern University; Brigham and Women's Hospital; Boston Children's Hospital; Boston Medical Center <br/><b>Active, not recruiting</b>

  38. A Nasal Treatment for COVID-19

    Thu, 28 May 2026 04:00:00 -0000

    <b>Conditions</b>: COVID-19; Healthy <br/><b>Interventions</b>: Drug: Optate; Drug: Placebo <br/><b>Sponsors</b>: Indiana University <br/><b>Active, not recruiting</b>

  39. A Spatial Analysis of Hotspots and Targeted Injection Settings Pilot Intervention for HIV Prevention Among People Who Inject Drugs

    Wed, 20 May 2026 04:00:00 -0000

    <b>Conditions</b>: COVID-19 <br/><b>Interventions</b>: Behavioral: Intervention test <br/><b>Sponsors</b>: Johns Hopkins Bloomberg School of Public Health; National Institutes of Health (NIH) <br/><b>Enrolling by invitation</b>

  40. AT1001 for the Treatment of Long COVID

    Fri, 22 May 2026 04:00:00 -0000

    <b>Conditions</b>: Long COVID; Long COVID-19; Post Acute COVID-19 Syndrome; Post Acute Sequelae of COVID-19 <br/><b>Interventions</b>: Drug: Larazotide Acetate; Drug: Placebo <br/><b>Sponsors</b>: Massachusetts General Hospital; Boston Children's Hospital, Boston, MA, USA <br/><b>Active, not recruiting</b>

  41. Brain-Training Treatment for Long COVID in Older Adults

    Tue, 26 May 2026 04:00:00 -0000

    <b>Conditions</b>: Post-Acute COVID-19 Syndrome <br/><b>Interventions</b>: Other: NeuroFlex (computerized gamified tasks) <br/><b>Sponsors</b>: UConn Health; National Institute on Aging (NIA) <br/><b>Active, not recruiting</b>

  42. Fatigability in Long COVID-19

    Mon, 18 May 2026 04:00:00 -0000

    <b>Conditions</b>: Long COVID <br/><b>Interventions</b>: Behavioral: Minimal-Dose Home-Based Resistance Exercise <br/><b>Sponsors</b>: VA Office of Research and Development <br/><b>Completed</b>

  43. A Study of Positive Emotions With Long COVID-19

    Fri, 29 May 2026 04:00:00 -0000

    <b>Conditions</b>: Post-Acute COVID-19 Syndrome <br/><b>Interventions</b>: Behavioral: Microdosing of mindfulness <br/><b>Sponsors</b>: University of California, Davis <br/><b>Active, not recruiting</b>

  44. A Vaccine Booster (GEO-CM04S1) for the Prevention of COVID-19 in Patients With Chronic Lymphocytic Leukemia

    Wed, 20 May 2026 04:00:00 -0000

    <b>Conditions</b>: Chronic Lymphocytic Leukemia; COVID-19 Infection <br/><b>Interventions</b>: Procedure: Biospecimen Collection; Biological: mRNA COVID-19 Vaccine; Biological: Synthetic MVA-based SARS-CoV-2 Vaccine COH04S1 <br/><b>Sponsors</b>: City of Hope Medical Center; National Cancer Institute (NCI) <br/><b>Suspended</b>

  45. A Brief Cognitive Task Intervention for NHS Staff Affected by COVID-19 Trauma (GAINS-2 Study)

    Wed, 27 May 2026 04:00:00 -0000

    <b>Conditions</b>: Intrusive Memories of Traumatic Event(s) <br/><b>Interventions</b>: Behavioral: Brief digital imagery-competing task; Behavioral: Brief digital music-listening task; Other: Treatment As Usual <br/><b>Sponsors</b>: P1vital Products Limited; Wellcome Trust; Uppsala University; Intensive Care Society (Communication Department); University of Nottingham <br/><b>Completed</b>

  46. Study to Evaluate Safety and Immunogenicity of COVID-19 Vaccine in Children 6 Months to < 12 Years

    Fri, 22 May 2026 04:00:00 -0000

    <b>Conditions</b>: COVID-19 <br/><b>Interventions</b>: Biological: SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period); Other: Placebo <br/><b>Sponsors</b>: Novavax <br/><b>Completed</b>

  47. Jump Start Plus COVID-19 Support

    Fri, 22 May 2026 04:00:00 -0000

    <b>Conditions</b>: Mental Health Wellness 1 <br/><b>Interventions</b>: Behavioral: Jump Start Plus COVID Support; Behavioral: Healthy Caregivers-Healthy Children (HC2) <br/><b>Sponsors</b>: University of Miami; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) <br/><b>Completed</b>

  48. Transplacental Transmission of RSV (TTRSV)

    Wed, 20 May 2026 04:00:00 -0000

    <b>Conditions</b>: SARS CoV 2 Infection; Respiratory Syncytial Virus (RSV); Bronchiolitis; Asthma <br/><b>Sponsors</b>: Tulane University; National Institutes of Health (NIH) <br/><b>Active, not recruiting</b>

  49. COVID-19 Experiences in the SELF Cohort

    Fri, 22 May 2026 04:00:00 -0000

    <b>Conditions</b>: COVID-19 <br/><b>Sponsors</b>: National Institute of Environmental Health Sciences (NIEHS) <br/><b>Enrolling by invitation</b>

  50. Immunotherapy for Neurological Post-Acute Sequelae of SARS-CoV-2

    Fri, 22 May 2026 04:00:00 -0000

    <b>Conditions</b>: Systemic Inflammation; Neuroinflammation; Microvascular Thrombosis <br/><b>Interventions</b>: Drug: IV normal saline; Drug: IV immunoglobulin <br/><b>Sponsors</b>: National Institute of Neurological Disorders and Stroke (NINDS) <br/><b>Enrolling by invitation</b>

  51. NIH RECOVER Tissue Pathology: Understanding the Long-Term Impact of COVID-19

    Fri, 29 May 2026 04:00:00 -0000

    <b>Conditions</b>: COVID-19; SARS CoV 2 Infection <br/><b>Sponsors</b>: NYU Langone Health <br/><b>Active, not recruiting</b>

  52. Evaluating the Immune Response to COVID19 Vaccination in Immunodeficient Patients

    Thu, 28 May 2026 04:00:00 -0000

    <b>Conditions</b>: Multiple Sclerosis; Autoimmune Blistering Disease; B-Cell Deficiency <br/><b>Interventions</b>: Biological: COVID19 vaccine <br/><b>Sponsors</b>: Yale University; National Institute of Allergy and Infectious Diseases (NIAID); Robert Leet and Clara Guthrie Patterson Trust <br/><b>Completed</b>

  53. COVID-19 and VA-LRTI: Second Versus First Wave of the Pandemic

    Fri, 22 May 2026 04:00:00 -0000

    <b>Conditions</b>: Severe COVID-19 <br/><b>Sponsors</b>: University Hospital, Lille <br/><b>Withdrawn</b>

  54. Evaluation of Immunologic Response Following COVID-19 Vaccination in Children, Adolescents, and Young Adults With Cancer

    Mon, 18 May 2026 04:00:00 -0000

    <b>Conditions</b>: COVID-19 Infection; Hematopoietic and Lymphatic System Neoplasm; Malignant Solid Neoplasm <br/><b>Interventions</b>: Procedure: Biospecimen Collection; Other: Survey Administration <br/><b>Sponsors</b>: Children's Oncology Group; National Cancer Institute (NCI) <br/><b>Active, not recruiting</b>

  55. REmotely Monitored, Mobile Health Supported Multidomain Rehabilitation Program With High Intensity Interval Training for COVID-19

    Thu, 28 May 2026 04:00:00 -0000

    <b>Conditions</b>: COVID-19; Critical Illness; ICU Acquired Weakness; PICS; Cardiorespiratory Fitness <br/><b>Interventions</b>: Behavioral: REmotely monitored, Mobile health supported Multidomain Rehabilitation Program with High Intensity Interval Training (REMM-HIIT) <br/><b>Sponsors</b>: Duke University; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Vanderbilt University Medical Center; Ohio State University; University of Kentucky; University of Alabama at Birmingham; Florida Atlantic University <br/><b>Recruiting</b>

  56. The Danish Pre-HCQ COVID Dialysis Study

    Tue, 19 May 2026 04:00:00 -0000

    <b>Conditions</b>: COVID-19; End Stage Renal Disease <br/><b>Interventions</b>: Drug: Hydroxychloroquine <br/><b>Sponsors</b>: Nicholas Carlson <br/><b>Withdrawn</b>

  57. Patient Perceptions of the Relational Empathy of Healthcare Practitioners From the Department of Emergency Medicine During the COVID-19 Pandemic

    Wed, 20 May 2026 04:00:00 -0000

    <b>Conditions</b>: COVID-19 Infection; Hematopoietic and Lymphoid Cell Neoplasm; Malignant Solid Neoplasm <br/><b>Interventions</b>: Other: Best Practice; Procedure: Discussion; Other: Questionnaire Administration <br/><b>Sponsors</b>: M.D. Anderson Cancer Center <br/><b>Active, not recruiting</b>

  58. Collection of SARS CoV-2 (COVID-19) Virus Secretions and Serum for Countermeasure Development

    Tue, 19 May 2026 04:00:00 -0000

    <b>Conditions</b>: Covid19 <br/><b>Sponsors</b>: Tulane University; Centers for Disease Control and Prevention; Gilead Sciences <br/><b>Recruiting</b>

  59. Perinatal Covid-19 Infection, NO Pathway, and Minipuberty

    Wed, 20 May 2026 04:00:00 -0000

    <b>Conditions</b>: Newborn, Infant, Disease; Neurodevelopmental Disorders <br/><b>Interventions</b>: Other: Inhaled NO; Other: routine care <br/><b>Sponsors</b>: University Hospital, Lille; European Commission <br/><b>Recruiting</b>

  60. Collection of the Thrombo-VaxCov Cohort

    Fri, 22 May 2026 04:00:00 -0000

    <b>Conditions</b>: Covid19; SARS-CoV Infection; Venous Thrombosis; Thrombocytopenia; Vaccination; Complications <br/><b>Interventions</b>: Other: Retrospective data and biological samples <br/><b>Sponsors</b>: University Hospital, Lille <br/><b>Withdrawn</b>

  61. Post COVID-19 Biorepository

    Fri, 22 May 2026 04:00:00 -0000

    <b>Conditions</b>: Coronavirus Infection <br/><b>Sponsors</b>: University of Kansas Medical Center <br/><b>Active, not recruiting</b>

  62. Incidence of Postoperative Delirium After Cardiac Surgery in Adults.

    Tue, 19 May 2026 04:00:00 -0000

    <b>Conditions</b>: Postoperative Delirium; Adult Cardiac Surgery; Covid19 <br/><b>Interventions</b>: Procedure: cardiac surgery <br/><b>Sponsors</b>: Medical University of Gdansk <br/><b>Completed</b>

  63. Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Children

    Thu, 28 May 2026 04:00:00 -0000

    <b>Conditions</b>: SARS-CoV-2 Infection, COVID-19 <br/><b>Interventions</b>: Biological: Biological/Vaccine: BNT162b2 10mcg; Biological: BNT162b2 20mcg; Biological: BNT162b2 30mcg; Other: Placebo; Biological: Biological/Vaccine: BNT162b2 3mcg <br/><b>Sponsors</b>: BioNTech SE; Pfizer <br/><b>Completed</b>

  64. Cardiovascular Manifestations of COVID-19

    Tue, 19 May 2026 04:00:00 -0000

    <b>Conditions</b>: COVID-19 <br/><b>Interventions</b>: Other: Chart review <br/><b>Sponsors</b>: Methodist Health System <br/><b>Withdrawn</b>

  65. Does COVID-19 Infection Increase the Risk of Pulmonary Embolism?

    Tue, 19 May 2026 04:00:00 -0000

    <b>Conditions</b>: Covid19; Pulmonary Embolism <br/><b>Interventions</b>: Diagnostic Test: Exposure: Positive COVID-19 infection; Diagnostic Test: Exposure: Negative COVID-19 infection <br/><b>Sponsors</b>: University of Aberdeen <br/><b>Completed</b>

  66. COVID-19 Pandemic Lockdown Effect in Adolescents and Young Adults With Type 1 Diabetes: Positive Results of an Unpreceded Challenge for Telemedicine and Patient Self-management

    Fri, 22 May 2026 04:00:00 -0000

    <b>Conditions</b>: Type 1 Diabetes <br/><b>Interventions</b>: Other: glucose control and sensor usage <br/><b>Sponsors</b>: Centre Hospitalier Sud Francilien <br/><b>Completed</b>

  67. Defibrotide for the Treatment of Severe COVID-19

    Tue, 26 May 2026 04:00:00 -0000

    <b>Conditions</b>: Covid19 <br/><b>Interventions</b>: Drug: Defibrotide <br/><b>Sponsors</b>: Brigham and Women's Hospital; Jazz Pharmaceuticals <br/><b>Recruiting</b>

  68. COVID-19 and Hereditary Metabolic Diseases

    Fri, 22 May 2026 04:00:00 -0000

    <b>Conditions</b>: Covid19; Metabolism, Inborn Errors <br/><b>Sponsors</b>: University Hospital, Lille <br/><b>Withdrawn</b>

  69. COVID-19 Biorepository

    Fri, 22 May 2026 04:00:00 -0000

    <b>Conditions</b>: Covid-19; SARS-CoV 2; Coronavirus; COVID <br/><b>Sponsors</b>: University of Kansas Medical Center <br/><b>Active, not recruiting</b>

  70. Study of Cord Blood Derived Mesenchymal Stem Cells for Treatment of Moderate, Severe or Critical Pneumonia

    Wed, 20 May 2026 04:00:00 -0000

    <b>Conditions</b>: COVID-19 Infection; COVID-19-Associated Acute Respiratory Distress Syndrome; Hematopoietic and Lymphoid Cell Neoplasm; Malignant Solid Neoplasm; Symptomatic COVID-19 Infection Laboratory-Confirmed <br/><b>Interventions</b>: Other: Best Practice; Biological: Mesenchymal Stem Cell <br/><b>Sponsors</b>: M.D. Anderson Cancer Center; National Cancer Institute (NCI) <br/><b>Active, not recruiting</b>

  71. Methodist Health System COVID-19 Patient Registry

    Tue, 19 May 2026 04:00:00 -0000

    <b>Conditions</b>: COVID-19 <br/><b>Interventions</b>: Other: Treatment for COVID-19 <br/><b>Sponsors</b>: Methodist Health System <br/><b>Completed</b>

  72. COVID-19 Follow up Intensive Care Studies

    Tue, 26 May 2026 04:00:00 -0000

    <b>Conditions</b>: Quality of Life; COVID-19 <br/><b>Sponsors</b>: University Medical Center Groningen; Hanze University of Applied Sciences Groningen <br/><b>Completed</b>

  73. Dietary Diversity of Young Children During CoVID-19 Outbreak: A Longitudinal Study

    Wed, 20 May 2026 04:00:00 -0000

    <b>Conditions</b>: Dietary Diversity <br/><b>Interventions</b>: Other: 2-weekly Food baskets <br/><b>Sponsors</b>: University of Malaya <br/><b>Completed</b>

  74. A Longitudinal Study of COVID-19 Sequelae and Immunity

    Fri, 22 May 2026 04:00:00 -0000

    <b>Conditions</b>: COVID-19 <br/><b>Sponsors</b>: National Institute of Allergy and Infectious Diseases (NIAID) <br/><b>Active, not recruiting</b>

  75. Cardiopulmonary Inflammation and Multi-System Imaging During the Clinical Course of COVID-19 Infection in Asymptomatic and Symptomatic Persons

    Fri, 29 May 2026 04:00:00 -0000

    <b>Conditions</b>: Acute and Long Term Effects of COVID-19 on Systemic Inflammation; Acute and Long Term Effects of COVID-19 on Lung Function; Acute and Long Term Effects of COVID-19 on Cardiac Function; Acute and Long Term Effects of COVID-19 on Kidney Function; Acute and Long Term Effects of COVID-19 on Brain Function <br/><b>Sponsors</b>: National Institutes of Health Clinical Center (CC) <br/><b>Completed</b>

  76. One-year Outcomes in Survivors of the Severe COVID-19 Pneumonia (CO-Qo-ICU)

    Tue, 26 May 2026 04:00:00 -0000

    <b>Conditions</b>: COVID; ARDS; Quality of Life <br/><b>Sponsors</b>: Centre Hospitalier Universitaire de Nice <br/><b>Active, not recruiting</b>

  77. NCI COVID-19 in Cancer Patients, NCCAPS Study

    Fri, 29 May 2026 04:00:00 -0000

    <b>Conditions</b>: COVID-19 Infection; Hematopoietic and Lymphatic System Neoplasm; Malignant Solid Neoplasm; Metastatic Malignant Solid Neoplasm <br/><b>Interventions</b>: Procedure: Biospecimen Collection; Other: Data Collection; Other: Quality-of-Life Assessment; Other: Questionnaire Administration <br/><b>Sponsors</b>: National Cancer Institute (NCI) <br/><b>Active, not recruiting</b>

  78. Convalescent Plasma Collection and Treatment in Pediatrics and Adults

    Fri, 29 May 2026 04:00:00 -0000

    <b>Conditions</b>: COVID19; Coronavirus Infection; Coronavirus; Virus Diseases; RNA Virus Infections <br/><b>Interventions</b>: Biological: Convalescent Plasma <br/><b>Sponsors</b>: West Virginia University <br/><b>Completed</b>

  79. Impact of Neck Inspiratory Muscle Activation During Sleep in ICU Patients After a COVID 19 ARDS

    Fri, 22 May 2026 04:00:00 -0000

    <b>Conditions</b>: ARDS; COVID-19 <br/><b>Interventions</b>: Other: PSG <br/><b>Sponsors</b>: University Hospital, Bordeaux <br/><b>Completed</b>

  80. INB03 for the Treatment of Pulmonary Complications From COVID-19

    Tue, 19 May 2026 04:00:00 -0000

    <b>Conditions</b>: COVID-19 <br/><b>Interventions</b>: Drug: INB03; Drug: Placebo <br/><b>Sponsors</b>: Inmune Bio, Inc. <br/><b>Terminated</b>

  81. Longitudinal Study of Covid-19 Infection Among HCW in a French University Hospital

    Fri, 22 May 2026 04:00:00 -0000

    <b>Conditions</b>: Sars-CoV2 <br/><b>Interventions</b>: Other: self-administered questionnaire; Diagnostic Test: SARS-Cov2 testing <br/><b>Sponsors</b>: University Hospital, Lille; Fondation Santé Roquette <br/><b>Withdrawn</b>

  82. Covid-19 in Patients With Chronic Inflammatory Rheumatism, Auto-immune or Auto-inflammatory Rare and Non-rare Diseases

    Fri, 22 May 2026 04:00:00 -0000

    <b>Conditions</b>: Sars-CoV2; Chronic Inflammatory Rheumatism; Autoimmune Diseases <br/><b>Sponsors</b>: University Hospital, Lille; FAI²R (Auto-immune and auto-inflammatory rare diseases French network) <br/><b>Completed</b>

  83. Trial of Treatments for COVID-19 in Hospitalized Adults

    Wed, 20 May 2026 04:00:00 -0000

    <b>Conditions</b>: Corona Virus Infection <br/><b>Interventions</b>: Drug: Remdesivir; Drug: Lopinavir/ritonavir; Drug: Interferon Beta-1A; Drug: Hydroxychloroquine; Other: Standard of care; Drug: AZD7442; Other: Placebo <br/><b>Sponsors</b>: Institut National de la Santé Et de la Recherche Médicale, France <br/><b>Completed</b>

  84. Viral Excretion in Contact Subjects at High/Moderate Risk of Coronavirus 2019-nCoV Infection. COVID-19.

    Tue, 26 May 2026 04:00:00 -0000

    <b>Conditions</b>: Coronavirus <br/><b>Interventions</b>: Biological: 2019-nCoV PCR <br/><b>Sponsors</b>: Institut National de la Santé Et de la Recherche Médicale, France <br/><b>Completed</b>

  85. Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study

    Mon, 18 May 2026 04:00:00 -0000

    <b>Conditions</b>: Lower Respiratory Tract Infection; Parainfluenza; Immunocompromised; COVID-19 <br/><b>Interventions</b>: Drug: DAS181; Drug: Placebo; Drug: DAS181 COVID-19; Drug: DAS181 OL <br/><b>Sponsors</b>: Ansun Biopharma, Inc. <br/><b>Recruiting</b>

  86. Viral Infections in Healthy and Immunocompromised Hosts

    Fri, 22 May 2026 04:00:00 -0000

    <b>Conditions</b>: Anogenital Herpes; COVID-19; Herpes Labialis <br/><b>Sponsors</b>: National Institute of Allergy and Infectious Diseases (NIAID) <br/><b>Recruiting</b>